[Federal Register Volume 71, Number 150 (Friday, August 4, 2006)]
[Notices]
[Pages 44314-44315]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E6-12599]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-273N]


Solicitation of Information on the Use of Tryptamine-Related 
Compounds

AGENCY: Drug Enforcement Administration (DEA), Justice.

ACTION: Notice of request for information.

-----------------------------------------------------------------------

SUMMARY: The DEA is soliciting information on substances that are 
related in chemical structure to tryptamine (see SUPPLEMENTARY 
INFORMATION). The Controlled Substances Act (CSA), in Title 21 of the 
United States Code (U.S.C. 812(c) Schedule I (Title 21 of the Code of 
Federal Regulations (CFR 1308.11(d)), lists certain tryptamines as 
Schedule I controlled substances. Some tryptamines that are not 
controlled under the CSA produce central nervous system effects that 
are similar to tryptamines that are controlled under the CSA. DEA is 
requesting information to help determine the impact on business if 
these substances were to be placed under control in the CSA.

DATES: Written comments must be postmarked, and electronic comments 
must be sent, on or before October 3, 2006.

ADDRESSES: To ensure proper handling of comments, please reference 
``Docket No. DEA-273N'' on all written and electronic correspondence. 
Written comments being sent via regular mail should be sent to the 
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration, Washington, DC 20537, Attention: DEA 
Federal Register Representative/ODL. Written comments sent via express 
mail should be sent to DEA Headquarters, Attention: DEA Federal 
Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, 
VA 22301. Comments may be directly sent to DEA electronically by 
sending an electronic message to [email protected]. 
Comments may also be sent electronically through http://www.regulations.gov using the electronic comment form provided on that 
site. An electronic copy of this document is also available at the 
http://www.regulations.gov Web site. DEA will accept attachments to 
electronic comments in Microsoft Word, WordPerfect, Adobe PDF, or Excel 
file formats only. DEA will not accept any file format other than those 
specifically listed here.

FOR FURTHER INFORMATION CONTACT: Christine A. Sannerud, Ph.D., Chief, 
Drug and Chemical Evaluation Section, Office of Diversion Control, Drug 
Enforcement Administration, Washington, DC 20537; Telephone: (202) 307-
7183.

SUPPLEMENTARY INFORMATION: Tryptamine is a compound in which the 
chemical structure can be described as indole substituted at the three 
position with an 2-aminoethyl chain. Although tryptamine itself is not 
a controlled substance, its chemical structure constitutes the skeletal 
makeup of tryptamines listed in Schedule I of the CSA, which are 
classified as hallucinogenic substances.
    Tryptamine is sometimes substituted on the indole ring or the 2-
aminoethyl chain or both with various substituents. Title 21 CFR 
1308.11(d) lists specific substituted tryptamines in Schedule I. Also 
included in Schedule I are the salts, isomers, and salts of isomers of 
the listed tryptamines. The term isomer, as used in this section, means 
the optical, geometric, and positional isomers.
    Individuals have published detailed methods of synthesis for 
substituted tryptamines and have reported pharmacological effects based 
on user experiences. Law enforcement personnel encounter such 
tryptamines, but because they are substituted differently than those 
listed or described in the CSA, they are not subject to direct control 
in Schedule I. However, some of these substances can be treated as 
Schedule I controlled substance analogues if intended for human 
consumption (21 U.S.C. 802(32); Sec.  813).
    DEA is soliciting information on (1) The commercial uses for 
tryptamines, (2) activities involving research and development, (3) 
tryptamines as intermediates or analytical standards, (4) import and 
domestic sources for tryptamines, and (5) any planned or anticipated 
uses for tryptamines. DEA invites interested persons to provide any 
information on the uses of tryptamines in industry, academia, research 
and development, or other applications. Both quantitative and 
qualitative information is sought.
    Although information is requested for all tryptamine substances 
regardless of substitutions, DEA is particularly interested in 
tryptamines that meet one

[[Page 44315]]

or more of the following conditions: (a) Has a secondary or tertiary 
amine formed by the substitution on the nitrogen atom of the 2-
aminoethyl chain by various alkyl groups, whether in chain or ring form 
(for example, N-alkyltryptamine, N,N-dialkyltryptamine, N,N-
tetramethylenetryptamine), (b) has an alkyl substitution on the alpha 
position of the 2-aminoethyl chain, and/or (c) has substituents on the 
indole ring system, including, but not restricted to, various alkyl 
chains, halogens, hydroxyl, alkoxy, acetyl, or alkylthio groups, at one 
or more positions except the one (indole nitrogen) position. DEA is 
especially interested in learning of the uses of the following 
tryptamines.

2-alpha-dimethyltryptamine
4-hydroxy-N,N-diisopropyltryptamine
4-hydroxy-N,N-dipropyltryptamine
4-hydroxy-N,N-tetramethylenetryptamine
4-hydroxy-N-isopropyl-N-methyltryptamine
4-hydroxy-N-methyl-N-propyltryptamine
5,6-dimethoxy-N-isopropyl-N-methyltryptamine
5-methoxy-alpha,N-dimethyltryptamine
5-methoxy-alpha-methyltryptamine
5-methoxy-N,N-dimethyl-2-methyltryptamine
5-methoxy-N,N-dimethyltryptamine
5-methoxy-N,N-tetramethylenetryptamine
5-methoxy-N-methyltryptamine
6-methoxy-1-methyl-1,2,3,4-tetrahydro-beta-carboline
7-methoxy-1-methyl-1,2,3,4-tetrahydro-beta-carboline
9,10-didehydro-6-allyl-N,N-diethylergoline-8-beta-carboxamide
9,10-didehydro-6-propyl-N,N-diethylergoline-8-beta-carboxamide
9,10-didehydro-N,N,6-triethylergoline-8-beta-carboxamide
alpha,N-dimethyltryptamine
N,N-dibutyltryptamine
N,N-dibutyl-4-hydroxytryptamine
N,N-diethyl-2-methyltryptamine
4-hydroxy-N,N-diethyltryptamine
N,N-diethyl-5-methoxytryptamine
N,N-diisopropyl-4,5-methylenedioxytryptamine
N,N-diisopropyl-5,6-methylenedioxytryptamine
N,N-diisopropyltryptamine
N,N-dimethyl-2-methyltryptamine
N,N-dimethyl-4,5-methylenedioxytryptamine
N,N-dimethyl-4-hydroxytryptamine
N,N-dimethyl-5,6-methylenedioxytryptamine
N,N-dimethyl-5-methylthiotryptamine
N,N-dipropyltryptamine
N,N-tetramethylenetryptamine
N-butyl-N-methyltryptamine
N-ethyl-4-hydroxy-N-methyltryptamine
N-ethyl-N-isopropyltryptamine
N-ethyltryptamine
4-methoxy-N-methyl-N-isopropyltryptamine
5-methoxy-N-methyl-N-isopropyltryptamine
N-isopropyl-N-methyl-5,6-methylenedioxytryptamine
N-isopropyl-N-methyltryptamine
N-methyltryptamine
4-acetoxy-N-methyl-N-isopropyltryptamine
4-acetoxy-N,N-diisopropyltryptamine
4-acetoxy-N,N-dipropyltryptamine
4-acetoxy-N,N-diethyltryptamine
5-methoxy-N,N-diallyltryptamine
5-methoxy-N-monoallyltryptamine
5-methoxy-N-methyl-N-isopropyltryptamin
N-methyl-N-isopropyltryptamine
4-hydroxy-N,N-diethyltryptamine
5-methoxy-N,N-diethyltryptamine

    Such information may be submitted to the Drug and Chemical 
Evaluation Section and is requested by October 3, 2006. Information 
designated as confidential or proprietary will be treated accordingly. 
Confidential business information is protected from disclosure under 
Exemption 4 of the Freedom of Information Act, 5 U.S.C. 552(b)(4)(FOIA) 
and the Department of Justice procedures set forth in 28 CFR 16.8.

    Dated: July 28, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control.
 [FR Doc. E6-12599 Filed 8-3-06; 8:45 am]
BILLING CODE 4410-09-P